DECOY THERAPEUTICS INC
DCOYNASDAQTrading Snapshot
- Day Range
- $4.14 – $4.23
- 52-Week Range
- $3.51 – $106.20
- Volume
- $1.97B
- Avg Volume
- $2.02B
- Shares Outstanding
- 530,000
- Next Earnings
- Oct 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $5M
- Last Q Revenue
- $1M
- P/E Ratio
- —
- P/S Ratio
- 0.5x
- EPS (TTM)
- $-1,011.67
- Dividend Yield
- —
Why Investors Own DCOY
- ✓High-growth profile — revenue up +37.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 39% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About DECOY THERAPEUTICS INC
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
U.S. CDC Says As Of August 6, 2,465 Confirmed Measles Cases Were Reported In U.S. In 2026; There Have Been 38 New Measles Outbreaks Reported In 2026, And 94% Of Confirmed Cases Are Outbreak-Associated
https://www.cdc.gov/measles/data-research/index.html
Decoy Therapeutics Announces The Expansion Of Its Intellectual Property Portfolio, Which Now Comprises Seven Patent Families
Portfolio now spans seven patent families and 19 pending applications across seven jurisdictions, protecting antiviral peptide conjugates, the methods used to make them, their formulations, and the design platform
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular session. The company's market cap stands at $100.9 million. Gossamer Bio (NASDAQ:GOSS) shares moved upwards by
Decoy Therapeutics Announces That One Of Its D-MAV Candidates Demonstrates In Vitro Activity Against Wild-Type Ebola Zaire Virus
Building on the result, Decoy has opened an exploratory program to design D-MAVs against filoviruses, including Ebola and Marburg. The candidate was engineered on Decoy's IMP3ACT™ platform to block coronavirus
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers AtaiBeckley (NASDAQ:ATAI) stock rose 34.3% to $7.2 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. Agape ATP (NASDAQ:ATPC) shares moved upwards by